Your browser doesn't support javascript.
loading
EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency.
Fu, Wenyan; Lei, Changhai; Yu, Yue; Liu, Shuowu; Li, Tian; Lin, Fangxing; Fan, Xiaoyan; Shen, Yafeng; Ding, Min; Tang, Ying; Ye, Xuting; Yang, Yongji; Hu, Shi.
Afiliação
  • Fu W; Department of Biophysics, College of Basic Medical Sciences, Second Military Medical University, Shanghai, China.
  • Lei C; Department of Obstetrics and Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China.
  • Yu Y; Department of Biophysics, College of Basic Medical Sciences, Second Military Medical University, Shanghai, China.
  • Liu S; Team SMMU-China of International Genetically Engineered Machine (iGEM) Competitions, Department of Biophysics, Second Military Medical University, Shanghai, China.
  • Li T; Department of Thyroid and Breast Surgery, First Affiliated Hospital, Second Military Medical University, Shanghai, China.
  • Lin F; Department of Biophysics, College of Basic Medical Sciences, Second Military Medical University, Shanghai, China.
  • Fan X; Team SMMU-China of International Genetically Engineered Machine (iGEM) Competitions, Department of Biophysics, Second Military Medical University, Shanghai, China.
  • Shen Y; Department of Biophysics, College of Basic Medical Sciences, Second Military Medical University, Shanghai, China.
  • Ding M; Team SMMU-China of International Genetically Engineered Machine (iGEM) Competitions, Department of Biophysics, Second Military Medical University, Shanghai, China.
  • Tang Y; Department of Biophysics, College of Basic Medical Sciences, Second Military Medical University, Shanghai, China.
  • Ye X; Department of Biophysics, College of Basic Medical Sciences, Second Military Medical University, Shanghai, China.
  • Yang Y; Department of Biophysics, College of Basic Medical Sciences, Second Military Medical University, Shanghai, China.
  • Hu S; Pharchoice Therapeutics Inc., Shanghai, China.
Clin Cancer Res ; 25(9): 2835-2847, 2019 05 01.
Article em En | MEDLINE | ID: mdl-30670492
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Protocolos de Quimioterapia Combinada Antineoplásica / Fosfatidilinositol 3-Quinases / Proteínas Proto-Oncogênicas c-akt / Receptores Notch / Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Protocolos de Quimioterapia Combinada Antineoplásica / Fosfatidilinositol 3-Quinases / Proteínas Proto-Oncogênicas c-akt / Receptores Notch / Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article